-
Mashup Score: 0
The rule includes a proposed unadjusted national average payment rate of US$21,376.53 for the device in 2024.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet
-
Mashup Score: 0Study explores use of imaging mass cytometry to identify therapeutic targets in kidney cancer - 9 month(s) ago
Researchers may be able to use imaging mass cytometry to capture and classify the tumor-immune evasion cell networks in clear cell renal cell carcinoma.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet-
Study explores the use of imaging mass cytometry to identify therapeutic targets in kidney cancer. #urology #urologist #kidneycancer Read more: https://t.co/fIStrjTLOE
-
-
Mashup Score: 0Olaparib shows promise in kidney cancer subtype - 9 month(s) ago
The PARP inhibitor olaparib demonstrated antitumor activity in patients with BAP1-mutated renal cell carcinoma.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet-
Olaparib shows promise in kidney cancer subtype https://t.co/ljTyAbuDyp #urology #urologist #kidneycancer #renalcellcarcinoma
-
-
Mashup Score: 2The take-home message from the TRAVERSE study of testosterone therapy - 10 month(s) ago
“For this population of patients…testosterone replacement therapy does appear to be safe from a cardiovascular standpoint,” says A. Michael Lincoff, MD.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet-
Dr. A. Michael Lincoff highlights the take-home message from the TRAVERSE study of testosterone therapy. #urology #urologist @LincoffMichael @CleClinicUro Watch now: https://t.co/CRPmxJMWCF
-
-
Mashup Score: 0Expert discusses advocacy for maintaining telemedicine reimbursement - 10 month(s) ago
“I think one of the hottest topics for advocacy right now relates to reimbursement for telemedicine,” says Amanda C. North, MD.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet-
Dr. Amanda C. North discusses advocacy for maintaining telemedicine reimbursement. #urology #urologist @anorth21 @MontefioreUro @MontefioreNYC Watch now: https://t.co/QCrp1IFd7e
-
-
Mashup Score: 0Genetic counselor discusses evolution of the field - 10 month(s) ago
“We are now doing more testing on the RNA side,” says Brittany M. Szymaniak, PhD, CGC.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet-
Dr. Brittany M. Szymaniak discusses how genetic counseling has evolved and gives advice for those considering a career in genetic counseling. #urology #urologist @NM_Urology Watch now: https://t.co/EkzP6oAf65
-
-
Mashup Score: 0HUMC Department of Urology achievements demonstrate commitment to leading the way in urological care - 10 month(s) ago
From urologic oncology and pediatric oncology to single port robotic surgery, the Department of Urology team is celebrating several achievements.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet-
HUMC Department of Urology achievements demonstrate commitment to leading the way in urological care. #urology #urologist @HUMCUrology Read more: https://t.co/bfFq0PmTMj
-
-
Mashup Score: 1Nivolumab combo improves survival in frontline urothelial carcinoma - 10 month(s) ago
Patients receiving nivolumab plus cisplatin-based chemotherapy lived longer than patients treated with standard chemotherapy alone.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet-
Nivolumab combo improves survival in frontline urothelial carcinoma, according to findings from a sub-study of the phase 3 CheckMate-901 trial. #urology #urologist Read more: https://t.co/BQTOkrSbxf
-
-
Mashup Score: 0FDA approves Optilume BPH System - 10 month(s) ago
The minimally invasive surgical therapy is approved for the treatment of lower urinary tract symptoms secondary to BPH.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet-
#ICYMI: The FDA has approved the Optilume BPH Catheter System for the treatment of lower urinary tract symptoms secondary to BPH. #urology #urologist Read more: https://t.co/Oy2lsQCyS5
-
-
Mashup Score: 0Study provides insight into the financial impact of treatment for metastatic prostate cancer - 10 month(s) ago
“Our most significant finding may be that patients experience financial toxicity despite their ability to remain compliant with treatment,” says Daniel D. Joyce, MD.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet-
A recent survey of patients with advanced prostate cancer showed that 54% experienced some level of financial toxicity related to the cost of treatment. #urology #urologist #pcsm #prostatecancer Read more on the findings here: https://t.co/RyzaPCpMIw
-
CMS 2024 proposed rule addresses eCoin reimbursement for urge urinary incontinence. #urology #urologist Read more: https://t.co/VVqQwt0OO8